An Open Label Clinical Study to Evaluate the Efficacy and Safety of Evecare Forte Liquid in PCOS (Polycystic Ovarian Syndrome)â??

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Women with signs and symptoms of PCOS like irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, hirsutism etc.
•2. History of PCOS with < 8 periods the preceding year.
•3. PCOS confirmed by Clinical and/or biochemical and/or ultrasonographical findings.
•4. Willingness to sign consent for study including participation with collection of blood specimens.

•1. Patients who is not using oral contraceptive pills, hormonal treatment or IUCDs.
•2. Patients who had no systemic illness like hypertension, renal disease, tuberculosis, hepatic disease, diabetes, coagulation disorder, etc.
•3. Patients with organic lesion of the reproductive tract especially any benign or malignant growth, extensive cervical erosion, cervical polyps, endometriosis.
•4. Patients with severe Hepatic/ cardiac/ mental illness.
•5. Patients unwilling to provide informed consent or abide by the requirements of the study.

发起方